Cardiotoxicity of anthracycline‑free targeted oncological therapies in HER2‑positive breast cancer (Review)
- Authors:
- Jingyuan Guan
- Mei Zhang
-
Affiliations: The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China - Published online on: December 8, 2020 https://doi.org/10.3892/ol.2020.12361
- Article Number: 100
-
Copyright: © Guan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Maajani K, Jalali A, Alipour S, Khodadost M, Tohidinik HR and Yazdani K: The global and regional survival rate of women with breast cancer: A systematic review and meta-analysis. Clin Breast Cancer. 19:165–177. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shan K, Lincoff AM and Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med. 125:47–58. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Vejpongsa P and Yeh E: Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. J Am Coll Cardiol. 64:938–945. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Eiermann W, Robert NJ, Giermek J, Martin M, Mackey J, Chan A, Pinter T, Valero V, Falkson C, et al: Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+early breast cancer. Cancer Res. 76 (Suppl 4):S5-04-S5-04. 2016. | |
|
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365:1273–1283. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, et al: Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, et al: Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19:1630–1640. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wadugu B and Kuehn B: The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol. 302:H2139–H2147. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cottin Y and Vergely C: Anthracyclines/trastuzumab: New aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci. 36:326–348. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, et al: Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: A multicentric analysis. Breast Cancer Res Treat. 173:319–328. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Valachis A, Nearchou A, Polyzos NP and Lind P: Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer. 133:2245–2252. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, et al: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 17:791–800. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rimawi M, Ferrero J, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C and Arpino G; PERTAIN Study Group, : First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): A randomized, open-label phase II trial. J Clin Oncol. 36:2826–2835. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hubalek M, Brantner C and Marth C: Role of pertuzumab in the treatment of HER2-positive breast cancer. Breast cancer (Dove Medical Press). 4:65–73. 2012.PubMed/NCBI | |
|
Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr and Leahy DJ: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 421:756–760. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM and Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 5:317–328. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, et al: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 380:617–628. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ponde N, Ameye L, Lambertini M, Paesmans M, Piccart M and de Azambuja E: Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. Eur J Cancer. 126:65–73. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355:2733–2743. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu W, Huang C, Yen C, Cheng A and Hsieh P: The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling. Theranostics. 8:3176–3188. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Choi HD and Chang MJ: Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: A meta-analysis. Breast Cancer Res Treat. 166:927–936. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li J and Gu J: Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of 77 randomized controlled trials. Clin. Drug Investg. 38:1109–1123. 2018. View Article : Google Scholar | |
|
Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G and Choueiri TK: QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 112:296–305. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, et al: Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer A phase 1b clinical trial. JAMA Oncol. 4:1214–1220. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Force T, Krause D and Van Etten R: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 7:332–344. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tomasovic A, Brand T, Schanbacher C, Kramer S, Hümmert MW, Godoy P, Schmidt-Heck W, Nordbeck P, Ludwig J, Homann S, et al: Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic Side-effects. Nat Commun. 11:17332020. View Article : Google Scholar : PubMed/NCBI | |
|
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al: 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 19:9–42. 2017. View Article : Google Scholar | |
|
Nickel AC, Patel A, Saba NF, Leon AR, El-Chami MF and Merchant FM: Incidence of cancer treatment-induced arrhythmia associated with novel targeted chemotherapeutic agents. J The Am Heart Assoc. 7:e0101012018. View Article : Google Scholar | |
|
Tamargo J, Caballero R and Delpon E: Cancer chemotherapy and cardiac arrhythmias: A review. Drug Safety. 38:129–152. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Herrmann J: Adverse cardiac effects of cancer therapies: Cardiotoxicity and arrhythmia. Nat Rev Cardiol. 17:474–502. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C and Roila F; ESMO Guidelines Working Group, : Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 23 (Suppl 7):S155–S166. 2012. View Article : Google Scholar | |
|
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al: Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 16:233–271. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA and Velazquez EJ: Guidelines for performing a comprehensive transthoracic echocardiographic examination in Adults: Recommendations from the American society of echocardiography. J Am Soc Echocardiogr. 32:1–64. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB and Marwick TH: Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 61:77–84. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA and Salcedo EE: Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: A systematic review and meta-analysis. J Am Coll Cardiol. 59:1799–1808. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA and Evangelisa A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 22:107–133. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, et al: The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 57:2263–2270. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, Domchek S, DeMichele A, Fox K, Shah P, et al: Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging. 13:198–210. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Timoteo AT, Moura Branco L, Filipe F, Galrinho A, Rio P, Portugal G, Oliveira S and Ferreira RC: Cardiotoxicity in breast cancer treatment: What about left ventricular diastolic function and left atrial function? Echocardiography. 36:1806–1813. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Yu Y, Zhang Y, Hao X, Zhao H, Yang S, Sun Q and Wang Y: Speckle tracking echocardiography in the early detection and prediction of anthracycline cardiotoxicity in diffuse large B-cell lymphoma treated with (R)-CHOP regimen. Echocardiography. 37:421–428. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Park J, Park J, Park J and Cho G: Global longitudinal strain to predict mortality in patients with acute heart failure. J Am Coll Cardiol. 71:1947–1957. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Velazquez EJ, Hassager C, Søgaard P and Køber L: Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. J Am Coll Cardiol. 61:2365–2373. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Laufer-Perl M, Arnold JH, Mor L, Amrami N, Derakhshesh M, Moshkovits Y, Sadeh B, Arbel Y, Topilsky Y and Rozenbaum Z: The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy. Clin Res Cardiol. 109:255–262. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A and Marwick TH: Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A sys. J Am Coll Cardiol. 63:2751–2768. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, et al: Assessment of Echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, Taxanes, and trastuzumab. Circ Cardiovasc Imaging. 5:596–603. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Santoro C, Esposito R, Lembo M, Sorrentino R, De Santo I, Luciano F, Casciano O, Giuliano M, De Placido S, Trimarco B, et al: Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 20:1345–1352. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bayar N, Küçükseymen S, Göktaş S and Arslan Ş: Right ventricle failure associated with trastuzumab. Ther Adv Drug Saf. 6:98–102. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Grover S, Leong DP, Chakrabarty A, Joerg L, Kotasek D, Cheong K, Joshi R, Joseph MX, DePasquale C, Koczwara B and Selvanayagam JB: Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: A prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol. 168:5465–5467. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zaidi A, Knight DS, Augustine DX, Harkness A, Oxborough D, Pearce K, Ring L, Robinson S, Stout M, Willis J, et al: Echocardiographic assessment of the right heart in adults: A practical guideline from the British Society of Echocardiography. Echo Res Pract. 7:G19–G41. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Keramida K and Farmakis D: Right ventricular involvement in cancer therapy-related cardiotoxicity: The emerging role of strain echocardiography. Heart Fail Rev. Mar 3–2020.(Epub ahead of print). doi: 10.1007/s10741-020-09938-8. View Article : Google Scholar : PubMed/NCBI | |
|
Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C and Cipolla CM: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 109:2749–2754. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Katsurada K, Ichida M, Sakuragi M, Takehara M, Hozumi Y and Kario K: High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy. Springerplus. 3:6202014. View Article : Google Scholar : PubMed/NCBI | |
|
Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J and Hildebrandt P: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 293:1609–1616. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, Di Mauro M, Ficorella C and Penco M: Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer. 105:1663–1668. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ekstein S, Nir A, Rein AJ, Perles Z, Bar-Oz B, Salpeter L, Algur N and Weintraub M: N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol. 29:440–444. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
van Boxtel W, Bulten BF, Mavinkurve-Groothuis AM, Bellersen L, Mandigers CM, Joosten LA, Kapusta L, de Geus-Oei LF and van Laarhoven HW: New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers. 20:143–148. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, et al: Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc. 9:e0147082020. View Article : Google Scholar : PubMed/NCBI | |
|
Michel L, Mincu RI, Mrotzek SM, Korste S, Neudorf U, Rassaf T and Totzeck M: Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis. ESC Heart Fail. 7:423–433. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Bao L, Chu B, Gao S, Lu M, Shi L, Fu L, Fang L and Xiang Q: Progressive elevation of NT-ProBNP during chemotherapy is related to asymptomatic cardiovascular events in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 19:167–176.e1. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pan W, Yang DH, Yu P and Yu HZ: Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions. BMC Cardiovasc Disord. 20:2082020. View Article : Google Scholar : PubMed/NCBI | |
|
Aula H, Skyttä T, Tuohinen S, Luukkaala T, Hämäläinen M, Virtanen V, Raatikainen P, Moilanen E and Kellokumpu-Lehtinen PL: ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast. 49:183–186. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang G, Zhai J, Huang X and Zheng D: Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Medicine. 97:e124472018. View Article : Google Scholar : PubMed/NCBI | |
|
Frères P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, Thiry J, Moonen M, Oury C, Lancellotti P, et al: Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer. 18:1022018. View Article : Google Scholar : PubMed/NCBI | |
|
Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, Picard MH, Carver JR, Halpern EF, Kuter I, et al: Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 61:1164–1172. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Knight D, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Kotecha T, et al: Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC. Cardiovasc Imaging. 12:823–833. 2019. | |
|
Tak T, Jaekel C, Gharacholou S, Dworak M and Marshall S: Measurement of ejection fraction by cardiac magnetic resonance imaging and echocardiography to monitor doxorubicin-induced cardiotoxicity. Int J Angiol. 29:45–51. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Armstrong G, Plana J, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, et al: Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 30:2876–2884. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ackrill A, et al: Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: A randomized phase II study (TRYPHAENA). Cancer Res. 71 (Suppl 24):S5–S6. 2011. | |
|
Du XL, Xia R, Burau K and Liu CC: Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Med Oncol. 28 (Suppl 1):S80–S90. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zamorano J, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, et al: 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 37:2768–2801. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, et al: Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 35:893–911. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, et al: Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 27:911–939. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Loap P, Kirov K and Kirova Y: Cardiotoxicity in breast cancer patients treated with radiation therapy: From evidences to controversies. Crit Rev Oncol Hematol. 156:1031212020. View Article : Google Scholar : PubMed/NCBI | |
|
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published, Nov 27, 2017. simplehttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5×11.pdf | |
|
Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, et al: ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for practice Guidelines (Writing Committee to Develop Guidelines for management of patients with ventricular arrhythmias and the prevention of Sudden Cardiac Death): Developed in Collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 114:e385–e484. 2006. View Article : Google Scholar : PubMed/NCBI |
